* Neoprofen acquisition did not violate antitrust laws
* Lundbeck says ruling has no financial effect
* Shares up 2.5 pct
(Adds company, analyst comment share reaction)
COPENHAGEN, Sept 9 (Reuters) - A U.S. court has ruled that Danish drugmaker Lundbeck's LUN.CO acquisition of heart defect drug Neoprofen did not reduce market competition, giving the company's shares a boost.
Lundbeck inherited the complaint in 2009 when it bought Ovation Pharmaceuticals Inc, which had bought the rights to market Neoprofen from Abbott Laboratories ABT.N.
“The U.S. Federal District Court has ruled in favour of Lundbeck and found no violation of the antitrust laws in the company’s acquisition of Neoprofen,” the Danish firm said in a statement.
Neoprofen is used in premature infants with patent ductus arteriosus (PDA), a condition in which a blood vessel in the heart fails to close after birth.
Lundbeck spokesman Mads Kronborg said the ruling had no financial impact. Shares in the firm, however, rose after the news to trade 2.5 percent up at 94.50 crowns at 1425 GMT.
“(The rise) shows the shares haven’t performed particularly well for a longer period, so any positive news are taken into account,” said Sydbank analyst Rune Dahl. (Reporting by Anna Ringstrom and Shida Chayesteh; Editing by Will Waterman)
Our Standards: The Thomson Reuters Trust Principles.